Thalidomide-S-C6-acid is a synthetic E3 ligase ligand -linker conjugate, consisting of a thalidomide-based cereblon ligand and one linker. It can be used to synthesize PROTAC Cas9 Degrader-1.

Deoxy-thalidomide-alkyne-hexanoic acid is a E3 ligase ligand-linker conjugate that can be used for synthesis of PROTAC degrader SD-91.

PROTAC BRD4 ligand-4 is a BRD4 ligand, which can be used to synthesize PROTAC BRD4 Degrader-37.

FAK ligand-5 (BI-4464) is a FAK inhibitor, with an IC50 of 25 nM. FAK ligand-5 can serve as a ligand for target protein for PROTAC, used in the development and design of degraders for PROTAC FAK. FAK ligand-5 can be used in the synthesis of PROTAC FAK degrader 4. FAK ligand-5 can be used in cancer research.

E3 Ligase Ligand-linker Conjugate 180 is an E3 ubiquitinase ligand-linker conjugate. E3 Ligase Ligand-linker Conjugate 180 can be used to synthesize KI-CDK9d-32.

PZ671 is a potent Bcl-xL PROTAC degrader with an IC50 of 1.3 nM (MOLT-4 cells) and a DC50 of 0.9 nM (Bcl-xL). PZ671 induces apoptosis in MOLT-4 cells. PZ671 effectively inhibits tumor growth and rapidly reverses transient platelet counts reduction in MOLT-4 xenograft mice. PZ671 can be used for the research of cancer, such as small cell lung cancer (SCLC).

BCL-xL ligand 2 is a ligand for BCL-xL. BCL-xL ligand 2 can be conjugated with E3 ligase Ligand and linker to synthesize Bcl-xL PROTAC degrader PZ671.

HDAC6 ligand-5 is a binding ligand of HDAC6 and can be used to synthesize PROTACs such as PROTAC HDAC6 degrader 5.

Adamantan-C-amide-PEG2-C2-amine (Compound 8) is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs, such as PROTAC β-NF-JQ1.

Pomalidomide-C2-PEG-NHCO-C2-COOH is a conjugate of the CRBN ligand and the linker (E3 Ligase Ligand-Linker Conjugate). Pomalidomide-C2-PEG-NHCO-C2-COOH can be used for synthesizing PROTAC ASK1 degrader dASK1.

dASK1 is a selective and cereblon (CRBN)-based PROTAC degrader of apoptosis signal-regulating kinase 1 (ASK1). dASK1 forms a stable ternary complex with ASK1, facilitating ASK1 rapid and sustained degradation via the ubiquitin-proteasome pathway. dASK1 demonstrates potent ASK1 degradation. dASK1 can be used for the research of steatohepatitis.

LD-110 is a highly efficient and effective PROTAC degrader targeting LSD1 (DC50 = 0.44 μM). LD-110 promotes LSD1 degradation and increases the level of H3K4 dimethylation in a ubiquitin-proteasome-dependent manner. LD-110 inhibits the growth and survival of multiple esophagus squamous cancer cell (ESCC) lines by inducing apoptosis. LD-110 can be used for the study of esophagus squamous cancer.

LAG-3 PROTAC-1 is a potent LAG-3 PROTAC degrader with a DC50 of 0.27 μM. LAG-3 PROTAC-1 can be used in cancer immunology research.

JWJ-01-378 is a selective TRK PROTAC degrader. JWJ-01-378 efficiently degrades WT TRK and TPM3-TRKA fusion proteins and inhibits downstream pERK signaling, while showing limited efficacy against TRK inhibitor resistant mutants and ALK fusions. JWJ-01-378 potently suppresses cancer cell proliferation.

dAurAB2 is a dual-degrading PROTAC that potently degrades Aurora-A and Aurora-B with DC50s of 59 nM and 39 nM, respectively. dAurAB2 reduces N-Myc levels in MYCN-amplified IMR32 neuroblastoma cells. dAurAB2 can be used for the study of neuroblastoma.

dAurAB5 is a dual Aurora-A (DC50 = 8.8 nM) and Aurora-B (DC50 = 6.1 nM) PROTAC degrader. dAurAB5 induces degradation of Aurora-A and Aurora-B, reduces N-Myc levels, and decreases viability in IMR32 neuroblastoma cells. dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. dAurAB5 can be used to study cancers such as neuroblastoma.

sEH-H ligand 2 is an sEH inhibitor and a ligand for the target protein for PROTAC (sEH). sEH-H ligand 2 can be used to synthesize PROTAC sEH-degrader-4.

VHL-SNAP2-5C is a SNAP-fusion protein PROTAC degrader basing on a self-labeling protein SNAP tag. VHL-SNAP2-5C by endogenous tagging enables the visualization and the selective depletion of a SNAP-fusion protein, such as CLCa andEGFP. Pink: SNAP-fusion protein ligand.

(S,S,S)-AHPC is an E3 ligase ligand. (S,S,S)-AHPC can be used for synthesis of PROTAC AH081.

sEH-H ligand 1 is a PROTAC target protein ligand that can be used to synthesize PROTAC sEH degrader-2.

CRBN ligand-184 is a ligand for CRBN-type E3 ubiquitin ligases. CRBN ligand-184 can be used to synthesize PROTAC AU-24118.

MNK1 ligand 1 (Compound 5) is a MNK1 ligand. MNK1 ligand 1 can be used for synthesis of PROTAC MNK1 degrader-1.

dASK1-VHL is an orally active PROTAC degrader targeting ASK1. dASK1-VHL can effectively bind VHL and promote the selective degradation of ASK1. dASK1-VHL effectively reduces ASK1 protein levels, inhibits the activation of p38 MAPK, and reduces liver lipid content. dASK1-VHL provides new ideas for the study of Metabolic dysfunction-associated steatohepatitis (MASH).

ASK1 ligand 1 is a binding ligand for ASK1 and can be used to synthesize PROTACs such as dASK1-VHL.

Thalidomide-PEG2-CH2-Boc-acid is a synthesized E3 ligase ligand-linker conjugate that can be used in the synthesis of PROTACs, such as MT-802.

MI1013 is a PROTAC PXR degrader (DC50 = 89 nM, Dmax = 82%). MI1013 degrades PXR in human hepatocellular carcinoma RG cells (HepaRG). MI1013 specifically and safely regulates CYP3A4 promoter activity through PXR degradation. MI1013 affects several key genes involved in sulfate conjugation (e.g., SULT1E1), bile acid synthesis (CYP7A1), gluconeogenesis (PCK1), ketone synthesis (HMGCS20), and hepatocyte proliferation (MKI67).

JP-163-16 is a RelA/p65 PROTAC degrader. JP-163-16 selectively reduces the expression of RelA/p65 in a proteasome-dependent manner in cells. JP-163-16 can induce cell apoptosis by inhibiting the NF-κB signaling pathway. JP-163-16 can be used for research on RelA/p65-dependent tumours, such as chronic lymphocytic leukaemia (CLL).

PRMT5 ligand 2 (Compound 38) is a PROTAC target protein ligand (Ligands for Target Protein for PROTACs). PRMT5 ligand 2 can be used for synthesis MS115.

MS115 is a selective PRMT5/MEP50 PROTAC degrader with DC50 values of 17.4 nM and 11.3 nM for PRMT5 and PRMT5 at 24 h in MDAMB468 cells, respectively. MS115 inhibits the proliferation of breast cancer cells.

Piperazine-CO-C1-Azacyclohexane-C1-Piperazine is a PROTAC linker can be used in the synthesis of PROTACs, such as PROTAC CDK4/6/9 degrader 1.